IL HB0004: MEDICAID-PHARMACY SERVICES
Illinois HB0004 proposes changes to Medicaid pharmacy services, potentially affecting prescription drug monitoring, dispensing, and compliance with DEA and board of pharmacy regulations.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies in Illinois should confirm how it applies to their specific situation before acting. There is a time constraint attached: TBD - monitor legislative progress; effective date likely upon passage or January 1, 2026.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill may alter Medicaid reimbursement, PDMP reporting requirements, or compounding standards (USP 795/797) for controlled substances.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies in Illinois
What you must do
Review the full bill text for specific changes to PDMP, e-prescribing, or dispensing rules; assess impact on operations and compliance.
Deadline
TBD - monitor legislative progress; effective date likely upon passage or January 1, 2026.
Source: https://ilga.gov/Legislation/RegularSession/HB?SessionId=114
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- TX HB 7: Relating to prohibitions on the manufacture and provision of abortion-inducing drugs, including the jurisdiction of and effect of certain judgments by courts within and outside this state with respect to the manufacture and provision of those drugs, and to protections from certain counteractions under the laws of other states and jurisdictions; authorizing qui tam actions.
- US-CONGRESS HR7895: PBM Kickback Prohibition Act
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability